Physician profile
Donna M Cipolla
NPI 1508845306
$3,232.78
in general payments reported to CMS, 2019-2025
31 companies · $116 in 2025
The $116 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,079 · 2020: $171 · 2021: $116 · 2022: $303 · 2023: $827 · 2024: $621 · 2025: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,537 · Education: $27.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,536.60 |
| Education | $27.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $732.26 | 2019-2025 | Skyrizi, Rinvoq |
| Takeda Pharmaceuticals U.S.A., INC. | $722.62 | 2019-2024 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $507.28 | 2019-2024 | Xifaxan |
| Janssen Biotech, INC. | $182.48 | 2019-2024 | Stelara, Tremfya, Simponi |
| Ironwood Pharmaceuticals, INC | $112.92 | 2019-2024 | Linzess |
| Gilead Sciences, INC. | $83.92 | 2019-2024 | |
| Intercept Pharmaceuticals, INC. | $75.59 | 2019-2024 | Ocaliva |
| Pfizer INC. | $73.98 | 2019-2024 | |
| Genzyme Corporation | $69.22 | 2022-2023 | |
| Allergan, INC. | $68.18 | 2019 | |
| Celgene Corporation | $61.99 | 2022-2023 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $56.97 | 2023 | Dupixent |
| Ucb, INC. | $54.27 | 2019 | |
| Nestle Healthcare Nutrition INC. | $51.50 | 2023 | |
| Blueprint Medicines Corporation | $36.93 | 2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $36.82 | 2024 | Voquezna |
| Shire North American Group INC | $36.31 | 2019 | |
| Merck Sharp & Dohme LLC | $34.12 | 2019 | |
| Qol Medical, LLC | $31.75 | 2019 | |
| Braintree Laboratories, INC. | $24.18 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.30 | 2023 | Cyltezo |
| Amgen INC. | $21.98 | 2020 | |
| Lilly USA, LLC | $21.14 | 2024 | Omvoh |
| Ardelyx, INC. | $19.78 | 2023 | Ibsrela |
| Celltrion USA INC. | $18.58 | 2024 | Zymfentra |
| Redhill Biopharma INC. | $16.81 | 2020 | |
| Exact Sciences Corporation | $16.36 | 2024 | Cologuard Collection Kit |
| Evoke Pharma, INC. | $15.64 | 2023 | Gimoti |
| Endo Pharmaceuticals INC. | $13.52 | 2019 | |
| Alfasigma USA, INC. | $12.38 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$77,759.52 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Cipolla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.